Targeted therapy combination extends survival in BRAF-mutant melanoma

CHICAGO — Adjuvant dabrafenib plus trametinib reduced mortality risk for adults with resected stage III BRAF V600-mutant melanoma, according to final results of the randomized phase 3 COMBI-AD trial.
The findings, presented at ASCO Annual Meeting, also reaffirmed 3- and 5-year updates on improved RFS and distant metastasis-free survival for individuals in the study’s treatment arm.
“Dabrafenib [Tafinlar, Novartis] and tramtetinib [Mekinist, Novartis] remains a standard-of-care choice as an adjuvant therapy for patients with resected stage III melanoma, especially given the

CHICAGO — Adjuvant dabrafenib plus trametinib reduced mortality risk for adults with resected stage III BRAF V600-mutant melanoma, according to final results of the randomized phase 3 COMBI-AD trial.
The findings, presented at ASCO Annual Meeting, also reaffirmed 3- and 5-year updates on improved RFS and distant metastasis-free survival for individuals in the study’s treatment arm.
“Dabrafenib [Tafinlar, Novartis] and tramtetinib [Mekinist, Novartis] remains a standard-of-care choice as an adjuvant therapy for patients with resected stage III melanoma, especially given the